Hyodeoxycholic acid inhibits colorectal cancer proliferation through the FXR/EREG/EGFR axis

Hyodeoxycholic acid inhibits colorectal cancer proliferation through the FXR/EREG/EGFR axis

BackgroundThe high morbidity and mortality rates of colorectal cancer (CRC) have been a public health concern globally, and the search for additional therapeutic options is imminent. Hyodeoxycholic acid (HDCA) has been receiving attention in recent years and has demonstrated potent efficacy in sever...

Full description

Saved in:

Bibliographic Details
Main Authors:	Qiang Pang, Shansong Huang, Xiaodong Li, Jiaqing Cao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Cell and Developmental Biology
Subjects:	colorectal cancer Hyodeoxycholic acid FXR EREG EGFR
Online Access:	https://www.frontiersin.org/articles/10.3389/fcell.2024.1480998/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Polysaccharides of Atractylodes Macrocephala Koidz Alleviate LPS-Induced Bursa of Fabricius Injury in Goslings by Inhibiting EREG Expression
by: Shuying Gong, et al.
Published: (2025-01-01)

EGFR inhibitors in the treatment of colorectal cancer
by: M. В. Zabelin, et al.
Published: (2018-09-01)

When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer
by: Pietro Paolo Vitiello, et al.
Published: (2025-02-01)

Study of the expression of oncoprotein p53, EGFR in colorectal carcinomas with different proliferative activity
by: I.S. Shponka, et al.
Published: (2023-04-01)

FXR Activation Accelerates Early Phase of Osteoblast Differentiation Through COX-2-PGE<sub>2</sub>-EP4 Axis in BMP-2-Induced Mouse Mesenchymal Stem Cells
by: Ko Fujimori, et al.
Published: (2024-12-01)

Hypoxia and lipid metabolism related genes drive proliferation migration and immune infiltration mechanisms in colorectal cancer subtyping
by: Shansong Huang, et al.
Published: (2025-01-01)

Clostridium Scindens Protects Against Vancomycin‐Induced Cholestasis and Liver Fibrosis by Activating Intestinal FXR‐FGF15/19 Signaling
by: Jintao Xiao, et al.
Published: (2025-02-01)

Gasdermin D regulates the activation of EGFR in colorectal cancer
by: Ying Li, et al.
Published: (2024-12-01)

Protective effects of Bifidobacterium breve on imiquimod-induced psoriasis in mice through secondary bile acid production and FXR-TLR4/NF-κB pathway
by: Xinqi Chen, et al.
Published: (2024-11-01)

Baicalein inhibits PRRSV through direct binding, targeting EGFR, and enhancing immune response
by: Jing Wu, et al.
Published: (2025-01-01)

Efficacy and Safety of Chemotherapy or EGFR‐TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China
by: Chen Liao, et al.
Published: (2025-01-01)

EGFR inhibition augments the therapeutic efficacy of the NAT10 inhibitor Remodelin in Colorectal cancer
by: Yongbin Zheng, et al.
Published: (2025-02-01)

Discovery of potent allosteric antibodies inhibiting EGFR
by: Léxane Fournier, et al.
Published: (2024-12-01)

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
by: Nathaniel J. Myall, MD, et al.
Published: (2025-02-01)

CircUCK2(2,3) promotes cancer progression and enhances synergistic cytotoxicity of lenvatinib with EGFR inhibitors via activating CNIH4–TGFα–EGFR signaling
by: Xindong Wei, et al.
Published: (2025-01-01)

Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in Nonsmall Cell Lung Cancer Patients With EGFR Mutation
by: Chang Dong Yeo, et al.
Published: (2025-01-01)

EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2024-11-01)

Vaccarin suppresses diabetic nephropathy through <?A3B2 pi6?>inhibiting the EGFR/ERK1/2 signaling pathway
by: Zhu Xuexue, et al.
Published: (2024-08-01)

Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients
by: Martina Ruglioni, et al.
Published: (2025-02-01)

Non-small Cell Lung Cancer Cell Line PC-9 Drug-resistant Mutant Cell Line  Establishment and Validation of Their Sensitivity to EGFR Inhibitors
by: Tao HU, et al.
Published: (2024-11-01)

EGFR as a biomarker of smoking status and survival in oropharyngeal squamous cell carcinoma
by: Shanmugappiriya Sivarajah, et al.
Published: (2019-01-01)

Design, synthesis, and apoptotic antiproliferative action of new benzimidazole/1,2,3-triazole hybrids as EGFR inhibitors
by: Alshimaa A. Y. Ahmed, et al.
Published: (2025-01-01)

Responsive afatinib treatment in high-grade salivary gland ductal carcinoma and NSCLC with uncommon EGFR mutations: Treatment outcomes
by: Sivakamavalli Jeyachandran
Published: (2024-06-01)

Emerging targeted therapies in oral oncology: Focus on EGFR inhibition
by: Vishnu Priya Veeraraghavan, et al.
Published: (2024-09-01)

Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK‐inhibitor‐induced tolerant persister cells in ALK‐fusion‐positive lung cancer
by: Koh Furugaki, et al.
Published: (2025-02-01)

Methyltransferase DNMT3B promotes colorectal cancer cell proliferation by inhibiting PLCG2
by: Ji Yong, et al.
Published: (2024-08-01)

EGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells
by: Bita Jafary, et al.
Published: (2025-01-01)

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
by: Shang‐Gin Wu, et al.
Published: (2025-01-01)

Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator’s Consortium Registry Analysis
by: Margaret Stalker, MD, et al.
Published: (2025-01-01)

Five-year follow-up study of stage I-IV rectal cancer including EGFR immunoexpression and p21 immunoactivity
by: Monika Kozłowska-Geller, et al.
Published: (2021-03-01)

Comparative analysis of EGFR mutations in circulating tumor DNA and primary tumor tissues from lung cancer patients using BEAMing PCR
by: Duhita Mirikar, et al.
Published: (2025-01-01)

Study of the association of the known prognostic variables with EGFR expression in head and neck squamous cell carcinomas
by: Toyaja Jadhav, et al.
Published: (2023-07-01)

A Novel Bacteriophage with the Potential to Inhibit <i>Fusobacterium nucleatum</i>-Induced Proliferation of Colorectal Cancer Cells
by: Ho Yin Pekkle Lam, et al.
Published: (2025-01-01)

Elucidating the potential of EGFR mutated NSCLC and identifying its multitargeted inhibitors
by: Anakha D. Rajeeve, et al.
Published: (2025-01-01)

Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan
by: Jerry Shu-Hung Kuo, et al.
Published: (2025-01-01)

Modulation of gut microbiota in targeted cancer therapy: insights on the EGFR/VEGF/KRAS pathways
by: Li Gong, et al.
Published: (2024-12-01)

Orthogonal validation of PROTAC mediated degradation of the integral membrane proteins EGFR and c-MET
by: Camilla Ruffilli, et al.
Published: (2025-01-01)

The Electric Field Guided HaCaT Cell Migration Through the EGFR/p38 MAPK/Akt Pathway
by: Huajian Zhou, et al.
Published: (2024-12-01)

Epsin3 promotes non-small cell lung cancer progression via modulating EGFR stability
by: Huiling Su, et al.
Published: (2025-02-01)

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
by: Jing Zhang, et al.
Published: (2025-02-01)